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Abstract
Background: Pharmacogenetic studies are essential in understanding the interindividual variability
of drug responses. DNA sample collection for genotyping is a critical step in genetic studies. A
method using dried blood samples from finger-puncture, collected on DNA-cards, has been
described as an alternative to the usual venepuncture technique. The purpose of this study is to
evaluate the implementation of the DNA cards method in a multicentre clinical trial, and to assess
the degree of investigators' satisfaction and the acceptance of the patients perceived by the
investigators.
Methods:  Blood samples were collected on DNA-cards. The quality and quantity of DNA
recovered were analyzed. Investigators were questioned regarding their general interest, previous
experience, safety issues, preferences and perceived patient satisfaction.
Results: 151 patients' blood samples were collected. Genotyping of GST polymorphisms was
achieved in all samples (100%). 28 investigators completed the survey. Investigators perceived
patient satisfaction as very good (60.7%) or good (39.3%), without reluctance to finger puncture.
Investigators preferred this method, which was considered safer and better than the usual
methods. All investigators would recommend using it in future genetic studies.
Conclusion: Within the clinical trial setting, the DNA-cards method was very well accepted by
investigators and patients (in perception of investigators), and was preferred to conventional
methods due to its ease of use and safety.
Background
Pharmacogenetic studies are essential both for under-
standing the variability of drug response observed among
patients and furthering the development of personalized
medicine [1-3]. Peripheral blood sample collection from
patients is a critical step in obtaining DNA for genetic or
pharmacogenetic studies. This may require the involve-
ment of different centres, couriers and laboratory
resources. A lack of laboratory resources or specialized
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personnel can restrict the participation of some medical
centres [4,5].
Blood samples obtained by venepuncture (the standard
DNA collection method) often cannot be used due to
medical, logistical or cultural reasons. Occasionally, use
of such samples is feasible, but prohibitively expensive.
This method is a labour-intensive way of obtaining DNA
at the doctor's office and is associated with potential secu-
rity problems. The sample must either be delivered rap-
idly to the central laboratory or frozen at the doctor's
office. Logistical difficulties in managing liquid or frozen
samples are associated with high costs [6, 7].
Recently, a new method has been described that is easier
to use, less invasive and much cheaper than the usual
venepuncture technique. This new method uses chemi-
cally treated paper cards, such as IsoCode Cards® or FTA
Cards®  (also known as DNA Cards). The DNA cards
method allows dried blood samples (obtained from fin-
gertip puncture) to be stored and transported at room
temperature [6,7]. High-quality genomic DNA can be
extracted from these samples and used for genetic analy-
sis, providing suitable archival media in DNA banks for
forensic [8] or genetic epidemiological studies [4].
Several authors have compared traditional methods and
the DNA cards method for collection of DNA samples
indicating some advantages of the blood spots and DNA
cards method for multicenter studies [7-9]. The DNA
cards method has been used to collect DNA samples in
several clinical studies focusing on infective pathogens,
such as malaria [5,10], staphylococcus [11], or HIV [12],
Gaucher disease [13] and cancer [4,14]. This method was
selected to perform a pharmacogenetic substudy. DNA
cards were used to obtain blood samples in a multicentre
clinical trial (ITEMS) in which the response to tegaserod
(Zelnorm®/Zelmac®, Novartis Pharmaceuticals AG), a
selective 5-HT4 receptor partial agonist, was evaluated in
patients with irritable bowel syndrome. The aims of the
present study were to evaluate the implementation of the
DNA cards method in a clinical trial, the quality and
quantity of DNA collected from patients, the investigators'
Sample blood collection diagram at doctor's office using the DNA cards method Figure 1
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satisfaction and their perception of the patients' satisfac-
tion with this method.
Methods
Study design and subjects
Patients from the ITEMS study [15] provided written,
informed consent to participate in the pharmacogenetic
substudy. The study protocol was approved by the Institu-
tional Review Boards of the 24 participating centres and
the Spanish Health Authorities. The ITEMS study person-
nel in these centres (hospital and primary care) were
involved in the collection procedure and the satisfaction
survey.
Sample collection using the DNA cards method
Each investigator received a blood sample collection kit,
comprising a plastic container with two DNA card devices
(IsoCode Cards®, Schleicher & Schuell/Whatman), an
automatic lancet, an alcohol-soaked towel, a Band-aid®,
two desiccant packs, a zip-sealed plastic bag, an instruc-
tions card and patient identification barcode labels.
Patient blood samples were obtained according to the
procedure shown in Figure 1. Several drops of blood from
a fingertip puncture were collected on each IsoCode Card®
and dried at room temperature for 30–40 minutes to sta-
bilize the sample. The IsoCode Cards® were then stored at
room temperature alongside the desiccant packs (to avoid
humidity) in the zip-sealed plastic bag, before being sent
(at the investigator's convenience) by standard courier to
the DNA bank for DNA purification (1–8 months after
blood collection).
DNA isolation and quantification
DNA was extracted using a modification of the manufac-
turer's instructions. Using a paper puncher, 1/8 inch (3.2
mm) discs were punched from the complete card matrix
region containing the dried blood. Between consecutive
uses, the puncher was sterilized with alcohol and flame
before making several punches through clean filter paper.
The discs containing dried blood were placed in a 1.5 mL
tube and heated in an oven at 80°C for 15–20 minutes. To
remove contaminants, the discs were washed twice with
500–750 µl of water and vortexed three times for 5 sec-
onds. The washed disc was transferred to a new tube and
12 µL of water was added per punch. The individual tubes
were incubated at 100°C for 15 minutes to elute the DNA
from the card matrix, before being stored on ice. The sam-
ples were pulse-vortexed about 60 times and centrifuged
for 1 minute at 13,000 x g. The matrix discs were removed
using plastic forceps, and squeezed on the side of the tube
to remove excess water. The eluate containing the purified
single-stranded DNA (ssDNA) was quantified and stored
at -80°C until required. ssDNA yields were determined as
instructed in the Oligreen ssDNA quantitation kit (Molec-
ular Probes) using a spectro-fluorometer (Hitachi F-
4500).
Genotyping quality control
The  GSTM1  and  GSTT1  polymorphisms were assayed
using a multiplex PCR based on a previously described
method [16]. GSTM1 (5'-GTG CCC TAC TTG ATT GAT
GGG-3', 5'-CTG GAT TGT AGC AGA TCA TGC-3') and
GSTT1 (5'-TTC CTT ACT GGT CCT CAC ATC TC-3', 5'-
TCA CCG GAT CAT GGC CAG CA-3') [17] primers were
used to amplify a 273 and 459 base-pair (bp) fragment,
respectively. The absence of both PCR products indicated
a deleted genotype. A 349 bp fragment of the human actin
gene was included as an internal PCR control (primers 5'-
GGG CAC GAA GGC TCA TCA TTC-3', 5'-TTT TTG GCT
TGA CTC AGG ATT-3'). Length specific PCR amplifica-
tions of the primer sets used were confirmed by an in sil-
ico search of the Genome sequence using the UCSC In-
Silico PCR software [18, 19]. PCR reactions were con-
ducted in a 50 µL volume at standard condition with 1.5
mM MgCl2, 4 µg/mL of each primer, 2.5 units of Amplitaq
(Applied Biosystems) and 25 ng of gDNA. The PCR
cycling conditions were: 5 minutes at 95°C followed by
95°C for 10 seconds, 61°C for 30 seconds and 72°C for
30 seconds during 30 cycles, with a final extension period
of 10 minutes at 72°C, performed in a Perkin Elmer 2400
cycler. Genotypes were identified by electrophoresis of the
amplified fragments through 2% agarose gels containing
ethidium bromide (0.5 mg/mL).
Satisfaction survey
Twenty-eight investigators (17 principal investigators, 5
co-investigators and 6 nurses) from 17 hospital outpatient
clinics and seven primary care centres were surveyed
regarding the DNA cards method. Questions focused on
general interest in pharmacogenetic studies, previous
experience of collecting blood samples, safety, preferred
methods of blood collection and perceived patient satis-
faction with the DNA cards method used.
Statistical analyses
All statistical analyses were performed using the SAS Sys-
tem® version 8.02 software (SAS Institute, Inc). Data were
summarized as mean (standard deviation [SD]) or n (%)
unless otherwise stated. Non-parametric procedures
(Kruskal-Wallis, Wilcoxon rank sum or Spearman correla-
tion test, as appropriate) were used to investigate a poten-
tial investigator effect, as well as the possible influence of
patient characteristics (gender, age, education level) on
the number of discs obtained from the DNA cards. Multi-
ple regression was used to build a predictive model of
DNA recovered from DNA cards. The significance of
regressors was based on Wald statistics.BMC Medical Genetics 2006, 7:45 http://www.biomedcentral.com/1471-2350/7/45
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Results
Blood collection and DNA analysis
Blood samples were obtained from 151 patients by 28
investigators using the DNA cards method. Four investiga-
tors reported previous experience of collecting samples for
genetic analysis. Samples were obtained at the doctor's
office and transported by courier to the DNA bank. Sam-
ples were stored at room temperature until use, with a var-
iable storage period ranging from 5 to 498 days (median
248 days). Deviations in the collection procedure were
observed in 62 of the 151 samples (41%) received by the
DNA bank. These included incorrect sealing of the bag (n
= 34, 55%), failure to include desiccant packs (n = 6,
10%), blood expanding out of the card collection region
(n = 15, 24%), cards arriving with no identification label
attached (n = 2, 3%), and others (n = 5, 8%). A small
amount of blood on the paper area (fewer than 17
punches or less than 30% of total area) was observed in
nine samples (6%).
The area of dried blood on the matrix card varied consid-
erably between samples. While some patients stained the
specimen cards completely, others stained only a small
portion of the cards. We obtained a range of 11 to 55
punched discs (1/8 inch) per patient, with a mean of 34.6
(10.0) discs (Table 1). The number of punched disc
obtained was heterogeneous among investigators
(Kruskall-Wallis test, p < 0.0001). None of the patients'
characteristics was associated with the number of discs
obtained from IsoCode Cards®.
DNA purification of the punched discs recovered 30–
4983 ng of ssDNA, with a mean of 1097.9 (± 789.7) ng
and a median of 962 ng. The yields of DNA per disc were
variable (range, 1.7–115.9 ng/disc) with a mean of 29.6
(± 18.1) ng of ssDNA per disc and a median of 26.5 ng.
Table 1 shows the frequency distribution of the extracted
quantities of DNA. The best-fit regression model of the
log-transformed amount of DNA (ng) accounted for 65%
of the total variance, including linear and quadratic terms
for the number of discs (p = 0.001 in both cases) and a lin-
ear term for storage time (p = 0.019). The regression equa-
tion obtained was:
ln [DNA] = 0.3038*p - 0.0034*p2 + 0.0018 t
where (p) is the number of punched discs and (t) is the
storage time expressed in days.
The quality of purified DNA was assessed by genotyping
the GST gene. Positive PCR amplifications were obtained
from all patient samples and their corresponding GST
genotypes at the first attempt (except in one case where a
second PCR analysis was performed) resulting in a 100%
success rate according to the presence/absence of the
length specific PCR products (Figure 2). The following
genotypes were identified: 82 patients (54.0%, 95%CI:
45.7–62.1%) had the GSTM1*0 genotype and 20 patients
(13.2%, 95%CI: 8.1–19.4%) had the GSTT1*0 genotype.
When analyzing the two loci simultaneously, 12 patients
(8%, 95%CI: 4.2–13.5%) had the combination
GSTM1*0/T1*0 genotype, and 63 patients (41.7%,
95%CI: 33.7–50.0%) had the combination GSTM1/T1.
No problems such as cross contamination or DNA degra-
dation occurred during the purification and genotyping
process. There were no significant differences in the qual-
ity and quantity of DNA recovered between specimens
collected correctly and specimens showing some of the
protocol violations reported earlier (Figure 2).
Example of GST genotypes obtained from blood samples col- lected using the DNA cards method Figure 2
Example of GST genotypes obtained from blood 
samples collected using the DNA cards method. Sam-
ples received with procedure deviations (lanes 1–4), col-
lected according to the study procedure (lanes 5–8), and 
samples with low DNA recovering (lanes 9–12).
Table 1: Frequency distribution of amounts of total DNA 
extracted, DNA concentration by punch and punch by DNA 
cards received at the DNA bank
Total ssDNA (ng) Samples (n) % Accumulative %
30–250 18 11.84 11.84
251–1000 59 38.82 50.66
1001–2000 52 34.21 84.87
2001–3000 21 13.82 98.68
>3000 2 1.32 100.00
ng ssDNA/punch
1–10 22 14.47 14.47
11–20 33 21.71 36.18
21–30 26 17.11 53.29
31–40 28 18.42 71.71
41–50 22 14.47 86.18
51–60 16 10.53 96.71
>60 5 3.29 100.00
Punch/card
11–20 11 7.24 7.24
21–30 31 20.39 27.63
31–40 48 31.58 59.21
41–50 52 34.21 93.42
>50 10 6.58 100.00BMC Medical Genetics 2006, 7:45 http://www.biomedcentral.com/1471-2350/7/45
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Satisfaction survey
Investigators from 22 of the 24 participating centres com-
pleted the survey. All 22 principal investigators and co-
investigators surveyed believed that it was interesting to
perform research studies that had a pharmacogenetic
component (Figure 3a). Most principal investigators
(86.4%) declared that, compared with venepuncture, use
of the DNA cards method would 'favourably' or 'very
favourably' influence their decision to participate in
future pharmacogenetic studies (Figure 3a).
Patient satisfaction with the DNA cards method (as per-
ceived by the 28 principal investigators, co-investigators
or nurses) was either 'very good' (n = 17, 60.7%) or 'good'
(n = 11, 39.3%). There was no reported resistance from
patients to the fingertip-puncture technique (Figure 3b).
Only five investigators reported problems obtaining suffi-
cient blood, all of which were associated with the finger-
tip-puncture process (difficulties with the lancet) or with
the application of blood onto the paper card.
When comparing the DNA cards method with other DNA
collection techniques (such as venepuncture or saliva
sampling), most investigators (n = 22, 78.6%) preferred
the DNA cards method due to ease of use. The DNA cards
method was also considered the safest blood-collecting
method (Figure 3c).
When asked for an overall assessment of the DNA cards
method, the majority of investigators (n = 22, 78.6%)
declared that the DNA cards method was the best option
for collecting DNA compared with other usual methods.
All 28 investigators indicated that they would recommend
using DNA cards for obtaining DNA samples in future
genetic studies (Figure 3d).
Discussion
We evaluated a DNA collection method that used DNA
cards in the context of a clinical trial with a pharmacoge-
netic substudy. We also assessed the impact of this
method on investigator satisfaction and their patients'
perceived satisfaction.
The results of this survey demonstrate a high level of
investigator satisfaction with the DNA cards method.
These findings corroborate data reported in other studies
using this methodology, which have focused on the views
and perceptions of the investigators [5,7]. DNA cards have
many advantages. When collecting blood, the investiga-
tors and patients stated their acceptance of, and preference
for, the DNA cards method compared with other collec-
tion techniques. From the investigators' perspective, the
DNA cards collection method using fingertip-puncture is
easily and quickly administered, which decreases the
staff's exposure to blood, therefore making this method
safer than other blood collection techniques. Addition-
ally, the cards are easy to label and handle, do not require
preprocessing at the doctor's office or cool storage (which
would require appropriate freezers at the centre). From
the patients' perspective, this method could be perceived
as minimally invasive, painless and easy to perform com-
pared with venepuncture collection.
The results of our model indicate that the storage period
has a slightly favourable influence on the recovery of DNA
from the cards, with an additional effect during the first 6
months (data not shown). These results are consistent
with previous studies, which reported very good DNA sta-
bility in dried blood samples on DNA cards stored at
room temperature for up to 16 months [7,8]. Other
authors have reported successful PCR analyses after 4 or
8.5 years of storage [20,21] and the manufacturer asserts
that it is possible to obtain PCR amplifications after 14
years of DNA storage (Whatman brochure). This stability
provides a great advantage over other methods, as it sim-
plifies trial logistics, management and costs. Transport,
storage, and DNA extraction can all be performed at room
temperature, making it easier to transport the samples
from the various collection centres to the central DNA
bank or laboratory. This drastically reduces the work nec-
essary for sample management, as well as lowering the
costs of the process for several reasons: fingertip puncture
is less labour intensive than venepuncture ; freezer or
refrigerator management and handling of frozen samples
is not needed, and low-temperature packaging and spe-
cialized couriers are not required. Additionally, the dura-
tion of storage after blood collection (before the sample
can be transported) is much longer than is possible with
fresh blood samples, allowing several samples to be trans-
ported together, thus reducing both the total number of
parcels transported and the associated control manage-
ment. This increased storage time also removes time con-
straints on receipt of samples at the central laboratory, as
blood samples do not require immediate processing after
delivery to the laboratory. In addition, transport by stand-
ard mail or courier is inexpensive (cards are compact and
lightweight), the cards are economical and require little
storage space [22], and the working time required for sam-
ple management by the investigators and study monitors
is shorter than with conventional methods based on liq-
uid or frozen sample handling. Based on our experience,
we estimated that using DNA Cards predicted a 56% sav-
ing in samples collection and management (material and
reagent cost, freezers, control and sample management,
transport of specimens and purification of DNA) as com-
pared to the alternative use of frozen samples. Conse-
quently, DNA cards were perceived as a cost-minimising
method to perform genetics analyses, as other authors
have pointed [6,22].BMC Medical Genetics 2006, 7:45 http://www.biomedcentral.com/1471-2350/7/45
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Satisfaction survey with DNA cards method Figure 3
Satisfaction survey with DNA cards method.
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There are traditional methods such as the use of buccal
mucus sampling that are non invasive alternative to blood
collection. Mouthwash allows to obtain genomic DNA of
high molecular weight from expectorations, an easy way
of sample collection for adults but not an option for
infants and small children where citobrush are required.
This method has been used in several large epidemiologic
studies showing that DNA obtained from buccal cells
allows PCR amplification but the yields of DNA are highly
variable between specimens and bacterial contamination
must be addressed [9]. The stability of the DNA is good
during 5 days allowing samples to be transported in fresh.
In order to increase the stability in time of the DNA from
buccal cells, it has been reported the use of DNA cards to
store this DNA during years at room temperature. Specific
formats of DNA cards have been developed including an
indicator to check the correct collection of buccal cells
over the modified matrix of the cards. The major advan-
tage of the collection of saliva in DNA cards is that is a
non-invasive method compared to fingerpunction, but
the disadvantage is that yield of DNA recovered from
saliva specimens are more variable than blood specimens
and sometimes is necessary to collect again samples of
subjects which have shown a low recovery of DNA from
their specimens [6,7,22]. Also there is the possibility of
coexistence of different genomes in the mouth, that could
interfere in some cases in the correct assignation of the
genotype of the subject.
The DNA obtained in this study was of sufficiently high
quality to perform PCR analysis after 16 months of stor-
age. Overall, the success rate for the PCR genotyping of the
GST gene was 100% according to the presence/absence of
the corresponding length specific PCR products. We have
only observed a problem with a single sample in our study
that could have been related to the low yield of DNA from
that particular sample. The method is robust for PCR anal-
ysis and the protocol violations observed (such as incor-
rect sealing of the bag and failure to include desiccant
packs) did not affect the quantity or quality of the purified
DNA. The frequencies of the GSTM1 (13.2 %) and GSTT1
(53.9%) genotypes are similar to those reported in other
studies of Caucasian populations from Spain [23] and the
differences are not statistically significant. Genotyping
analysis of the SNP rs2281820 locus (corresponding to
the motilin gene) in a subset of 140 samples showed that
genotype frequencies are in Hardy-Weinberg equilibrium
(data not shown) indicating that DNA samples collected
by this method do not generate methodological or sam-
pling problems for genotyping. At present, the method is
evaluated for other genotyping techniques, such as min-
isequencing (CYP2C9) or Taqman [24], without prob-
lems until now (data not shown).
The main disadvantage of the DNA cards method is the
quantity of DNA recovered compared with the yields
obtained with fresh venous blood samples. The mean of
1043 ng (median = 901 ng) of purified DNA per patient
that we obtained from two paper cards was considerably
less than the usual quantities (5–10 µg) obtained from the
purification of 0.3 mL of fresh or frozen whole blood by
affinity columns or cell lysis and protein precipitation
methods [25]. This observation could be explained partly
by the fact that 40% of the DNA is retained on the card
matrix [6]. In addition, the amount of DNA is highly var-
iable between patient specimens, due to intrinsic factors
such as the proportion of white blood cells in the blood
[7] and, primarily, to the quantity of blood actually
deposited on the card matrix (as shown in our model). As
reported here, this last factor is influenced by the investi-
gator, who should be aware of the importance of com-
pletely staining the sample collection area of the card. It is,
therefore, important that study monitors instruct the
investigators of the need to stain the entire sample card
with the patient's blood, to maximize the quantity of
DNA recovered.
The amount of DNA purified from the DNA cards could
be problematic for use in molecular analyses requiring
quantities of micrograms, such as Southern blot or
genomic cloning, but is suitable for use in SNP analyses.
The amount of DNA obtained potentially allows dozens
to hundreds of polymorphisms to be analysed using mul-
tiplexed PCR analyses. This capacity for analysis of poly-
morphisms is usually sufficient to achieve the objectives
of pharmacogenetic studies, if the genes involved in the
pharmacokinetic and pharmacodynamic pathways are
known. If more polymorphism analyses are required, or
in the case of recovering lower quantities of DNA from
patients, investigators will need to use any one of the
whole genome amplification methods that have been
published, such as multiple displacement amplification
[26], to obtain a sufficient quantity of genomic DNA for
analysis. Epigenetic modifications have been described to
be an important mechanism for gene regulation and dis-
ease [27]. At present only one paper has reported the use
of DNA cards to perform methylation studies [28]. If DNA
Cards have to be used for analyses of genomic methyla-
tion which requires DNA chemical modification, such as
methylation specific PCR (MSP) technique, it may be nec-
essary to carry out a previous study to validate the use of
DNA cards for these techniques. 
In the satisfaction survey, all investigators would recom-
mend using the DNA cards method in future genetic stud-
ies, due to its ease of use and its safety. The principal
investigators from the centres surveyed showed interest in
carrying out further pharmacogenetic studies, indicating
that the availability of the DNA cards method wouldBMC Medical Genetics 2006, 7:45 http://www.biomedcentral.com/1471-2350/7/45
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favourably influence their decision to participate in simi-
lar studies in the future. Based on investigator satisfaction,
the DNA cards technique could be the method of choice
for collecting DNA samples in phase III or IV clinical trials
evaluating the genetic influence of several (1–100) poly-
morphisms in patients' response to a pharmacological
treatment. Clinical trials typically involve multiple cen-
tres, sometimes with varying levels of laboratory
resources, DNA cards are thus a logical and practical
choice.
Conclusion
Within a clinical trial setting, the DNA-cards method was
very well accepted by investigators and patients (in per-
ception of investigators), and was preferred to conven-
tional methods due to its ease of use and safety. This
method is very robust allowing to obtain DNA of quality
to perform PCR analyses and obtain the GSTM1 and
GSTT1 genotype of all patients of the study. Overall, the
DNA-cards method is a tool that facilitates genetic and
pharmacogenetic testing in the usual clinical practice at
doctor's office.
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